These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations. Zheng WS; Hu YL; Guan LX; Peng B; Wang SY Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943 [TBL] [Abstract][Full Text] [Related]
5. CD25 expression on residual leukemic blasts at the time of allogeneic hematopoietic stem cell transplant predicts relapse in patients with acute myeloid leukemia without complete remission. Ikegawa S; Doki N; Kurosawa S; Yamaguchi T; Sakaguchi M; Harada K; Yamamoto K; Hino Y; Shingai N; Senoo Y; Hattori K; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Sakamaki H; Haraguchi K; Okuyama Y; Ohashi K Leuk Lymphoma; 2016; 57(6):1375-81. PubMed ID: 26422713 [TBL] [Abstract][Full Text] [Related]
7. Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia. De Luca L; Trino S; Laurenzana I; Tagliaferri D; Falco G; Grieco V; Bianchino G; Nozza F; Campia V; D'Alessio F; La Rocca F; Caivano A; Villani O; Cilloni D; Musto P; Del Vecchio L Cell Death Dis; 2017 Jun; 8(6):e2849. PubMed ID: 28569789 [TBL] [Abstract][Full Text] [Related]
8. Sorafenib as a Salvage Therapy in FLT3-ITD Negative Relapse/ Refractory Acute Myeloid Leukemia. Yang N; Gu Z; Liu Z; Huang W; Wang S; Wang L; Gao C Anticancer Agents Med Chem; 2018; 18(10):1489-1494. PubMed ID: 29521250 [TBL] [Abstract][Full Text] [Related]
9. [Significance of id4 promoter methylation in monitoring AML patients with completely remission]. Zhao Y; Wang QS; Li HH; Bo J; Dou LP; Jing Y; Wang SH; Yu L Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):476-8. PubMed ID: 18549611 [TBL] [Abstract][Full Text] [Related]
10. Mouse acute leukemia develops independent of self-renewal and differentiation potentials in hematopoietic stem and progenitor cells. Dong F; Bai H; Wang X; Zhang S; Wang Z; Xie M; Zhang S; Wang J; Hao S; Cheng T; Ema H Blood Adv; 2019 Feb; 3(3):419-431. PubMed ID: 30733302 [TBL] [Abstract][Full Text] [Related]
11. S100A9 induces differentiation of acute myeloid leukemia cells through TLR4. Laouedj M; Tardif MR; Gil L; Raquil MA; Lachhab A; Pelletier M; Tessier PA; Barabé F Blood; 2017 Apr; 129(14):1980-1990. PubMed ID: 28137827 [TBL] [Abstract][Full Text] [Related]
12. Prognostic Role of Postinduction Minimal Residual Disease and Myeloid Sarcoma Type Extramedullary Involvement in Pediatric RUNX1-RUNX1T1 (+) Acute Myeloid Leukemia. Lee JW; Kim S; Jang PS; Chung NG; Cho B; Im SA; Kim M J Pediatr Hematol Oncol; 2020 Apr; 42(3):e132-e139. PubMed ID: 31688618 [TBL] [Abstract][Full Text] [Related]
13. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia. Witte KE; Ahlers J; Schäfer I; André M; Kerst G; Scheel-Walter HG; Schwarze CP; Pfeiffer M; Lang P; Handgretinger R; Ebinger M Pediatr Hematol Oncol; 2011 Mar; 28(2):91-9. PubMed ID: 21214408 [TBL] [Abstract][Full Text] [Related]
14. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy. Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632 [TBL] [Abstract][Full Text] [Related]
15. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Baer MR; Stewart CC; Dodge RK; Leget G; Sulé N; Mrózek K; Schiffer CA; Powell BL; Kolitz JE; Moore JO; Stone RM; Davey FR; Carroll AJ; Larson RA; Bloomfield CD Blood; 2001 Jun; 97(11):3574-80. PubMed ID: 11369653 [TBL] [Abstract][Full Text] [Related]
16. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Cloos J; Goemans BF; Hess CJ; van Oostveen JW; Waisfisz Q; Corthals S; de Lange D; Boeckx N; Hählen K; Reinhardt D; Creutzig U; Schuurhuis GJ; Zwaan ChM; Kaspers GJ Leukemia; 2006 Jul; 20(7):1217-20. PubMed ID: 16642044 [TBL] [Abstract][Full Text] [Related]
17. Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia. McKenzie MD; Ghisi M; Oxley EP; Ngo S; Cimmino L; Esnault C; Liu R; Salmon JM; Bell CC; Ahmed N; Erlichster M; Witkowski MT; Liu GJ; Chopin M; Dakic A; Simankowicz E; Pomilio G; Vu T; Krsmanovic P; Su S; Tian L; Baldwin TM; Zalcenstein DA; DiRago L; Wang S; Metcalf D; Johnstone RW; Croker BA; Lancaster GI; Murphy AJ; Naik SH; Nutt SL; Pospisil V; Schroeder T; Wall M; Dawson MA; Wei AH; de Thé H; Ritchie ME; Zuber J; Dickins RA Cell Stem Cell; 2019 Aug; 25(2):258-272.e9. PubMed ID: 31374198 [TBL] [Abstract][Full Text] [Related]